TG Therapeutics (NASDAQ:TGTX) Lifted to Buy at StockNews.com

StockNews.com upgraded shares of TG Therapeutics (NASDAQ:TGTX – Free Report) from a hold rating to a buy rating in a research note released on Tuesday morning. TGTX has been the topic of a number of other reports. HC Wainwright raised their price objective on TG Therapeutics from $41.00 to $45.00 and gave the company a […]

Related Keywords

Virginia , United States , Laurencen Charney , , Jpmorgan Chase Co , Tg Therapeutics Inc , York Mellon Corp , Securities Exchange Commission , Charles Schwab Investment Management Inc , Somerset Trust Co , Jefferies Financial Group , Free Report , Financial Group , Moderate Buy , Get Free Report , Exchange Commission , Director Laurence , Schwab Investment Management , Retirement Systems , New York Mellon Corp , Rhumbline Advisers , Tg Therapeutics , Nasdaq Tgtx , Tgtx , Medical , Upgrade , Stocknews Com ,